Metabolism, excretion, and pharmacokinetics of (3,3-difluoropyrrolidin-1- yl)((2s,4s)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human

Drug Metabolism and Disposition

Volumn 40, Issue 11, 2012, Pages 2143-2161

  Sharma, Raman ^a,b   Sun, Hao ^a,b   Piotrowski, David W ^a,b   Ryder, Tim F ^a,b   Doran, Shawn D ^a,b   Dai, Haiqing ^a,b   Prakash, Chandra ^a,b  

^a PFIZER INC   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3 DIFLUOROPYRROLIDIN 1 YL[4 [4 (PYRIMIDIN 2 YL)PIPERAZIN 1 YL]PYRROLIDIN 2 YL]METHANONE; 3,3 DIFLUOROPYRROLIDIN 1 YL[4 [4 (PYRIMIDIN 2 YL)PIPERAZIN 1 YL]PYRROLIDIN 2 YL]METHANONE C 14; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PF 00734200; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY;

AMIDES; ANIMALS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DOGS; FECES; FEMALE; HUMANS; HYDROLYSIS; HYDROXYLATION; MALE; METABOLIC DETOXICATION, PHASE II; MICROSOMES, LIVER; MOLECULAR DOCKING SIMULATION; PIPERAZINES; PYRIMIDINES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84867678052     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.047316     Document Type: Article

References (23)

1. Ahrén B (2005) Inhibition of dipeptidyl peptidase-4 (DPP-4)-a novel approach to treat type 2 diabetes. Curr Enzyme Inhibition 1:65-73.
2. Caplow M (1968) Kinetics of carbamate formation and breakdown. J Am Chem Soc 90:6795-6803.
3. Flint A, Raben A, Astrup A, and Holst JJ (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520. (Pubitemid 28084232)
4. Hamilton RA, Garnett WR, and Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413. (Pubitemid 11134120)
5. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, and Holst JJ (1994) Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 43:104-108. (Pubitemid 24047112)
6. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
7. King H, Aubert RE, and Herman WH (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431. (Pubitemid 28405191)
8. Masuda K, Ito Y, Horiguchi M, and Fujita H (2005) Studies on the solvent dependence of the carbamic acid formation from ω-(1-naphthyl)alkylamines and carbon dioxide. Tetrahedron 61:213-229. (Pubitemid 39573420)
9. Mentlein R (2005) Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. Expert Opin Investig Drugs 14:57-64.
10. Miao Z, Sun H, Liras J, and Prakash C (2012) Excretion, metabolism, and pharmacokinetics of 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4- (ethylamino)piperidine-4-carboxamide, a selective cannabinoid receptor antagonist, in healthy male volunteers. Drug Metab Dispos 40:568-578.
11. Morrow JS, Keim P, and Gurd FR (1974) CO2 adducts of certain amino acids, peptides, and sperm whale myoglobin studied by carbon 13 and proton nuclear magnetic resonance. J Biol Chem 249:7484-7494.
12. Nathan DM, Schreiber E, Fogel H, Mojsov S, and Habener JF (1992) Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276.
13. Nielsen LL (2005) Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 10:703-710.
14. Perfetti R, Zhou J, Doyle ME, and Egan JM (2000) Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141:4600-4605. (Pubitemid 32055138)
15. Prakash C and Cui D (1997) Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites. Drug Metab Dispos 25:1395-1406. (Pubitemid 28010926)
16. Prakash C, Cui D, Baxter JG, Bright GM, Miceli J, and Wilner K (1998) Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers. Drug Metab Dispos 26:448-456. (Pubitemid 28223885)
17. Ritzel R, Orskov C, Holst JJ, and Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose response-relationships. Diabetologia 38:720-725.
18. Sun H (2012) Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism. Bioorg Med Chem Lett 22:989-995.
19. Sun H, Bessire AJ, and Vaz A (2012) Dirlotapide as a model substrate to refine structure-based drug design strategies on CYP3A4-catalyzed metabolism. Bioorg Med Chem Lett 22:371-376.
20. Sun H and Scott DO (2010) Structure-based drug metabolism predictions for drug design. Chem Biol Drug Des 75:3-17.
21. Sun H and Scott DO (2011) Metabolism of 4-aminopiperidine drugs by cytochrome P450s: molecular and quantum mechanical insights into drug design. ACS Med Chem Lett 2:638-643.
22. Wang A, Savas U, Hsu MH, Stout CD, and Johnson EF (2012) Crystal structure of human cytochrome P450 2D6 with prinomastat bound. J Biol Chem 287:10834 -10843.
23. Zimmet P (2003) The burden of type 2 diabetes: are we doing enough? Diabetes Metab 29:6S9-6S18.